RxDoctor Payments Data

Carabeth Russell, MD

Internal Medicine · Knoxville, TNNPI 1861604183

Payments from drug & device makers

$250in general payments, 2019–2025

Across 15 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$65
  • AbbVie$53
  • GSK$50
  • Philips North America LLC$23
  • Boehringer Ingelheim$22
  • Astellas Pharma US Inc$16
  • plus $21 from 2 others

What the payments were for

  • Food & beverage$250100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen4$65
AbbVie3$53
GSK3$50
Philips North America LLC1$23
Boehringer Ingelheim1$22
Astellas Pharma US Inc1$16
Novartis1$13
Inogen, Inc.1$8

How this compares

$250 in reported general payments places this provider in the 50th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$169,800
Medicare patients
324
Services billed
11,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$102,851
EliquisApixaban63$79,747
MounjaroTirzepatide65$62,368
XareltoRivaroxaban53$46,570
JardianceEmpagliflozin21$36,272
JanuviaSitagliptin Phosphate24$23,828
LinzessLinaclotide17$19,828
ShingrixVaricella-Zoster Ge/As01b/Pf44$9,822
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$8,836
SynthroidLevothyroxine Sodium107$8,031
Incruse ElliptaUmeclidinium Bromide13$7,534
PremarinEstrogens, Conjugated20$7,353
Breo ElliptaFluticasone/Vilanterol14$6,715
FarxigaDapagliflozin Propanediol11$6,366
Levothyroxine Sodium456$4,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$22$36,27221 claims
AbbVieLinzess, Synthroid$53$27,858124 claims
GSKShingrix, Incruse Ellipta, Breo Ellipta$50$24,07171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →